BAREŠ, Martin, Irena REKTOROVÁ, Robert JECH, Kateřina FARNÍKOVÁ, Jan ROTH, Evžen RŮŽIČKA, Petr KAŇOVSKÝ, Ivan REKTOR, Tomáš PAVLÍK, Leona UHLÍŘOVÁ and Jaroslav VYDLÁK. Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson’s disease? Journal of Neural Transmission, 2012, vol. 119, No 3, p. 373–380. ISSN 0300-9564. doi:10.1007/s00702-011-0683-9.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson’s disease?
Authors BAREŠ, Martin (203 Czech Republic, guarantor, belonging to the institution), Irena REKTOROVÁ (203 Czech Republic, belonging to the institution), Robert JECH (203 Czech Republic), Kateřina FARNÍKOVÁ (203 Czech Republic), Jan ROTH (203 Czech Republic), Evžen RŮŽIČKA (203 Czech Republic), Petr KAŇOVSKÝ (203 Czech Republic), Ivan REKTOR (203 Czech Republic, belonging to the institution), Tomáš PAVLÍK (203 Czech Republic, belonging to the institution), Leona UHLÍŘOVÁ (203 Czech Republic) and Jaroslav VYDLÁK (203 Czech Republic).
Edition Journal of Neural Transmission, 2012, 0300-9564.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30000 3. Medical and Health Sciences
Country of publisher Austria
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.052
RIV identification code RIV/00216224:14110/12:00059524
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1007/s00702-011-0683-9
UT WoS 000300587900010
Keywords in English Wearing-off; Parkinson’s disease; Levodopa; WOQ-9; Epidemiology
Tags International impact
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 16/4/2013 16:34.
Abstract
EWO (Epidemiology of Wearing-Off symptoms among the population of Parkinson’s disease (PD) patients on L-DOPA) is a multicentric, non-interventional, epidemiological and exploratory trial, focused on patients with PD who are treated with L-DOPA. The primary objective is the estimation of wearing-off symptoms (based on WOQ-9 questionnaire and assessment by neurologists) among PD patients who are treated with L-DOPA. From September 30, 2007 to June 30, 2008 altogether 563 valid records of PD patients were collected in movement disorders centers (Level A and Level B centers). Wearing-off symptoms were observed in 66.7% of PD patients (neurologists’ assessment) and in 90.6% of PD patients (WOQ-9 questionnaire). The biggest discrepancy was found in PD patients treated with L-DOPA for 0–2 years. The probability of detecting wearing-off by the neurologists strongly correlated with the highest number of positive responses in the WOQ-9 marked by PD patients. There was significant difference in the diagnosis of wearing-off between Level A centers (77.7%) and Level B centers (62.0%). When motor and non-motor symptoms in the WOQ-9 were considered, the difference between neurologists came from the detection of non-motor symptoms (lower in the Level B centers). The neurologists’ assessment of wearing-off symptoms and PD patients’ subjective evaluation of the WOQ-9 is based on the experience of the neurologist and on the detection of the non-motor symptoms of wearing-off. Careful explanation of the WOQ-9 questionnaire and improved awareness of the non-motor symptoms of wearing-off is strongly suggested.
PrintDisplayed: 24/11/2020 17:17